KHK抗体;KHK Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: HepG2, Hela cell, Mouse liver tissue lysates, Primary antibody: P13700(KHK Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 40 seconds    

  
  

**Background of KHK Antibodies**

Ketohexokinase (KHK), also known as fructokinase, is a critical enzyme in fructose metabolism, catalyzing the first step of fructose utilization by converting it to fructose-1-phosphate. KHK exists in two isoforms, KHK-A (ubiquitous, low-activity) and KHK-C (tissue-specific, high-activity), with expression predominantly in the liver, kidney, and intestine. Dysregulation of KHK is linked to metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), insulin resistance, and obesity, due to the role of excessive fructose intake in modern diets.

KHK antibodies are essential tools for studying the enzyme’s expression, localization, and function in both physiological and pathological contexts. They enable detection of KHK isoforms via techniques like Western blotting, immunohistochemistry, and ELISA, aiding research on tissue-specific metabolic pathways. Additionally, these antibodies help explore KHK’s involvement in fructose-induced toxicity, inflammation, and mitochondrial dysfunction, providing insights into disease mechanisms. Recent studies also highlight KHK as a potential therapeutic target, spurring interest in inhibitors for metabolic syndrome management.

Commercial KHK antibodies are typically validated for specificity toward KHK-A or KHK-C, with applications in preclinical models and human samples. Their development supports advancing understanding of fructose metabolism’s impact on health and disease.